Search - tctmd.com

Displaying 161 - 180 of 196

Sort: Relevancy | Date

News Daily News

Comparativas Indirectas revelan que hay Pocas Diferencias entre Nuevos Anticoagulantes

August 14, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

L.A. McKeown

August 09, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

News Daily News

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Jason Kahn

June 22, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

L.A. McKeown

June 06, 2012

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Daily News

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

May 04, 2012

News Daily News

Los Nuevos Anticoagulantes Orales Superan a la Warfarina en la Prevención del ACV en pacientes con Fibrilación Auricular

May 04, 2012

Presentation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Presenter: Corey S. Miller

May 03, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Daily News

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Caitlin E. Cox

April 26, 2012

Presentation

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Presenter: M. Patel

April 25, 2012

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

News Daily News

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

L.A. McKeown

January 09, 2012

Advertisement

Comparativas Indirectas revelan que hay Pocas Diferencias entre Nuevos Anticoagulantes

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Rivaroxaban May be Cost-Effective for A-fib Patients

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

Los Nuevos Anticoagulantes Orales Superan a la Warfarina en la Prevención del ACV en pacientes con Fibrilación Auricular

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content